JIITA

Advanced Chemiluminescent Immunoassay for the Early Diagnosis of Pancreatic Cancer

JIITA, vol. 2, no. 2, pp.70-75, Jun, 2018

DOI: soon

Advanced Chemiluminescent Immunoassay for the Early Diagnosis of Pancreatic Cancer

Hyun Seok Moon 1), Jae Ho Ko 1,3), Ho Sang Song 3,*), Junhyun Chong 4), Min Jae Kim 4), Ji Hoon Lee 4,*)

1) Sungsan ENG, Gumi, Gyeongbuk, Rep. of Korea
2) Department of Applied Chemistry, Kumoh National Institute of Technology, Gumi, Gyeongbuk, Ref. of Korea
3) MeDIoT LTD, Gumi, Gyeongbuk, Rep. of Korea
4) Luminescent MD, LLC, Hagerstown, MD 21742, United States

Abstract: A biosensor capable of rapidly quantifying trace levels of CA 19-9 using an enzyme-free immunoassay with 1,1’oxalayldiimidazole chemiluminescent (ODI-CL) detection was developed. The highly sensitive enzymefree immunoassay with ODI-CL detection can rapidly quantify CA 19-9 in human serum. This research demonstrates how the biosensor can be applied as an advanced bioanalytical method for the early diagnosis and accurate prognosis of pancreatic cancer. We anticipate that the biosensor can also be used to rapidly quantify various different tumor markers for the early diagnoses of human cancers

Keyword: Carbohydrate antigen 19-9 (CA 19-9), 1,1-Oxalyldiimidazole chemiluminescence (ODI-CL) ; Enzyme free immunoassay ; Tumor
marker ; Pancreatic cancer

Full Paper: